Author: Galvis, A. E.; Morphew, T.; Ehwerhemuepha, L.; Osborne, S.; Enriquez, C.; Imfeld, K.; Hoag, J.; Nieves, D.; Ashouri, N.; Jajist, Singh Nugent D.; Arrieta, A.
Title: The safety and antibody kinetics of COVID-19 convalescent plasma for the treatment of moderate to severe cases of SARS-CoV-2 infection in pediatric patients Cord-id: 51np5tya Document date: 2021_1_1
ID: 51np5tya
Snippet: Introduction: A novel Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the pathogen responsible for a serious, life threatening respiratory infection (COVID-19) initially reported in Wuhan, China which rapidly spread worldwide resulting in global pandemic. Multiple immunological and pharmacological therapies have been evaluated with variable results. Convalescent plasma has been used in previous outbreaks such as Influenza 1918 and 2009, Ebola, MERS and SARS with go
Document: Introduction: A novel Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the pathogen responsible for a serious, life threatening respiratory infection (COVID-19) initially reported in Wuhan, China which rapidly spread worldwide resulting in global pandemic. Multiple immunological and pharmacological therapies have been evaluated with variable results. Convalescent plasma has been used in previous outbreaks such as Influenza 1918 and 2009, Ebola, MERS and SARS with good efficacy and safety reported. There have been multiple large reports on the safety of COVID-19 convalescent plasma (CCP) for the treatment of this serious infection in the adults;controversy has ensued regarding its efficacy. Pediatric data on CCP use are limited.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date